How the EU's Falsified Medicines Directive Safety Features Are Shaping Regulatory Affairs Work in Europe

Introduction

The EU's Falsified Medicines Directive, known across the industry simply as the FMD, has been in force for years, but the safety features requirement it introduced continues to shape day-to-day regulatory affairs work for any company selling prescription medicines in Europe. The directive itself set the policy goal: keep falsified medicines out of the legitimate supply chain. The delegated regulation on safety features, Regulation (EU) 2016/161, is where the practical obligations live, and it's the part regulatory affairs teams interact with most directly, even though the physical infrastructure behind it is built and operated by other functions.

For professionals newer to the European market, or coming from a US-focused role where the comparable framework is the Drug Supply Chain Security Act, it's worth understanding how the FMD's safety features requirement actually touches regulatory affairs work, as distinct from the supply chain and packaging operations teams who own much of the day-to-day execution. This article walks through what the requirement covers, where regulatory affairs sits in the process, and what it means for people building a career working EU dossiers.

What the Safety Features Requirement Actually Requires

Since the safety features became mandatory, most prescription medicines placed on the EU market must carry two physical features on their outer packaging: a unique identifier, typically a 2D data matrix code encoding product, batch, expiry, and a serial number, and an anti-tampering device that shows visible evidence if the pack has been opened. The unique identifier is uploaded to a European hub and verified at the point of dispensing, which is how the system catches packs that don't match what was legitimately placed into the supply chain. Pharmacists and other authorized dispensers scan the code before handing a pack to a patient, and a mismatch triggers an investigation rather than automatically blocking the sale, since legitimate administrative errors do happen.

A short list of product categories is exempt or subject to different treatment, and a small number of non-prescription products were added to scope because of a documented falsification risk, so the exemption list isn't static. Keeping track of which SKUs fall in or out of scope, and under what conditions, is itself a piece of regulatory intelligence work that someone on the team needs to own, since getting it wrong either creates unnecessary packaging cost or, worse, leaves a product non-compliant.

Where Regulatory Affairs Fits Into the Work

Serialization and pack verification are largely operational and IT-driven, run by supply chain, manufacturing, and packaging teams who manage the data matrix printing, the connection to national and European verification systems, and the physical tamper-evidence engineering. But regulatory affairs sits at several points that make the requirement unavoidable in submission work. Packaging artwork for any new marketing authorization or variation in the EU has to reflect the correct placement and specification of the unique identifier and anti-tampering device, and that artwork goes through the same regulatory approval pathway as any other labeling change. A packaging change that looks purely cosmetic from a marketing standpoint can still require a variation filing if it touches how the safety features are presented or applied, which is a distinction that trips up teams who haven't worked through it before.

Regulatory affairs teams also need to track which National Competent Authority or national verification organization requirements apply on top of the EU-wide baseline, since some member states layer in additional national rules, for example around how the unique identifier interacts with national reimbursement coding or pricing approval processes. For companies managing a portfolio across many EU markets, this means the safety features requirement isn't a single compliance checkbox but an ongoing piece of per-market regulatory maintenance that has to be revisited every time a new market is added or a packaging specification changes.

Parallel trade and repackaging add another layer. Parallel distributors who relabel or repackage a product for a different EU market have their own obligations to replace or reapply safety features correctly, and the regulatory documentation supporting that repackaging has to demonstrate the safety features chain hasn't been broken. Regulatory professionals supporting parallel import dossiers spend real time on this specific piece of the submission, coordinating with the parallel distributor's own regulatory team to confirm the replacement features meet the same technical specification as the original.

What This Means for Regulatory Affairs Hiring and Skills

Companies building out EU regulatory affairs teams, particularly ones expanding their European footprint for the first time, increasingly look for candidates who understand how packaging and labeling variations interact with the safety features framework, not just general EU labeling rules. This shows up most clearly in CMC-adjacent regulatory roles and in regulatory operations functions that sit close to packaging artwork management, where fluency in the variation classification rules around safety features can meaningfully speed up a submission timeline.

It's also a useful topic to be conversant in in interviews for roles touching the European market, since it's a concrete, well-documented example of how a packaging requirement becomes a regulatory filing obligation, which is exactly the kind of cross-functional reasoning hiring managers tend to probe for. Being able to describe, even briefly, how a safety features-related packaging change would flow through to a variation filing shows an interviewer you understand the mechanics of EU regulatory work rather than just its vocabulary.

Common Compliance Pitfalls Regulatory Teams Run Into

A few mistakes come up repeatedly for companies newer to the EU market or expanding into it for the first time. One is treating the safety features requirement as purely an operations and IT problem and failing to loop regulatory affairs into packaging artwork decisions early enough, which creates rework when a variation filing turns out to be necessary after artwork has already been finalized with manufacturing. Another is assuming that because a product is compliant in one EU member state, it's automatically compliant everywhere, when in practice national layering of the requirement means market-by-market verification is still necessary.

A third, more subtle pitfall involves product transfers and divestitures. When a marketing authorization changes hands, whether through an acquisition, a licensing deal, or a portfolio divestiture, the safety features connection to the relevant national and European systems has to be properly transferred along with the authorization itself. Regulatory affairs teams managing a product transfer need to treat this as a formal workstream rather than an afterthought, since a gap in that transfer can leave a compliant product temporarily unable to be dispensed.

How the Requirement Has Evolved Since It Took Effect

Since safety features became mandatory, the scope of exempted and included products has been revisited more than once, and the practical experience of running the system for several years has surfaced edge cases that weren't fully anticipated at the outset, particularly around hospital dispensing workflows, sample medicines, and products that move between EU and non-EU markets as part of a broader global supply chain. Regulatory affairs professionals working in this space need to treat the requirement as a living piece of policy rather than a fixed rule learned once and never revisited, which is true of most European pharmaceutical regulation but especially true here given how operationally complex the underlying system is.

Companies that have been through a national regulator audit or inspection touching on safety features compliance often find that the areas of greatest scrutiny are exactly the ones described above: artwork and variation alignment, national layering, and product transfer continuity, rather than the core technology itself, which by now is well understood across the industry.

What This Looks Like Day to Day for a Regulatory Affairs Professional

In practice, most regulatory affairs professionals don't spend their time thinking about serialization in the abstract; they encounter it embedded in ordinary submission work. A labeling update to a package insert might trigger a parallel review of whether the outer carton artwork, including the safety features placement, still meets specification. A new market launch brings a checklist item to confirm which national verification organization the product needs to connect to and what lead time that connection requires before launch. A product recall, handled separately by quality and pharmacovigilance, often still involves regulatory affairs confirming how the safety features data supports identifying and tracing the affected batches.

None of this requires a regulatory affairs professional to be a serialization engineer. What it requires is enough fluency to know when a change touches the safety features framework, so the right specialist gets looped in before a submission goes out rather than after a health authority flags a gap. That judgment, knowing where your own expertise ends and when to pull in supply chain or packaging operations colleagues, is itself a skill worth developing deliberately.

Conclusion

The FMD's safety features requirement is a good example of a regulation that looks, on the surface, like someone else's problem; the physical packaging feature and the verification database are built and run by supply chain and IT. But the submission obligations that flow from it sit squarely with regulatory affairs. Understanding where that line falls, staying current on which products and member-state variations apply, and knowing how packaging changes map onto the variation classification system is a practical piece of expertise that pays off for anyone working EU dossiers, whether you're new to the market or have been filing there for years.